Over 10 years, pediatric PCV20 vaccination was dominant versus PCV13 and PCV15, projecting to avert up to 499,151 disease cases and save up to £1.509 billion.
Is pediatric PCV20 vaccination cost-effective compared to PCV13 and PCV15 in UK children?
Pediatric PCV20 implementation in the UK is projected to be economically dominant compared to PCV13 and PCV15, averting substantial disease cases and saving costs.
BACKGROUND: Despite the significant impact of longstanding pediatric pneumococcal conjugate vaccine (PCV) use in the United Kingdom (UK), pneumococcal disease burden remains substantial. Higher‑valent vaccines such as the 20‑valent PCV (PCV20) could reduce this burden, yet their value in the contemporary UK setting has not been fully assessed using recent data. RESEARCH DESIGN AND METHODS: An age-structured dynamic transmission model used post-COVID-19 UK epidemiology (2001-2023) to compare pediatric PCV20 (2 + 1 and 1 + 1) with PCV13 (1 + 1) and PCV15 (1 + 1). Over 10-years, we assessed cost-effectiveness and number needed to vaccinate (NNV), capturing disease cases, deaths, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Sensitivity and scenario analyses examined key uncertainties. RESULTS: Over 10 years, both PCV20 schedules were dominant versus PCV13 and PCV15. Versus PCV13, PCV20 1 + 1 and 2 + 1 were projected to avert 448,432 and 499,151 disease cases and save £1.509 and £1.306 billion, respectively. Versus PCV15, PCV20 1 + 1 and 2 + 1 were projected to avert 409,459 and 460,179 disease cases and save £1.424 and £1.221 billion, respectively. NNVs versus PCV13 were lower for PCV20 than PCV15 across both dosing schedules. Sensitivity and scenario results were consistent with the base-case. CONCLUSION: Pediatric PCV20 implementation in the UK could deliver substantial health gains while improving economic efficiency.
Warren et al. (Wed,) conducted a other in Pneumococcal disease. PCV20 vs. PCV13 (1 + 1) and PCV15 (1 + 1) was evaluated on Cost-effectiveness, number needed to vaccinate (NNV), disease cases, deaths, costs, QALYs, and ICERs. Over 10 years, pediatric PCV20 vaccination was dominant versus PCV13 and PCV15, projecting to avert up to 499,151 disease cases and save up to £1.509 billion.